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Abstract: Chemical immobilisation of pinnipeds is a routine procedure in research and veterinary 
practice. Yet, there are inevitable risks associated with chemical immobilisation, and the physiolog-
ical response to anaesthetic agents in pinnipeds remains poorly understood. The current study used 
wearable continuous-wave near-infrared spectroscopy (NIRS) data from 10 trials of prolonged an-
aesthesia (0.5 to 1.4 h) induced through ketamine and midazolam in five grey seals (Halichoerus 
grypus) involved in other procedures. The aim of this study was to (1) analyse the effect of each 
compound on heart rate, arterial oxygen saturation (SpO2), and relative concentration changes in 
oxygenated [ΔO2Hb] and deoxygenated haemoglobin [ΔHHb] in cerebral tissue and (2) to investi-
gate the use of NIRS as a real-time physiological monitoring tool during chemical immobilisation. 
Average group responses of ketamine (n = 27) and midazolam (n = 11) administrations were mod-
elled using generalised additive mixed models (GAMM) for each dependent variable. Following 
ketamine and midazolam administration, [ΔHHb] increased and [ΔO2Hb] remained relatively sta-
ble, which was indicative of apnoea. Periods of apnoea were confirmed from respiratory band data, 
which were simultaneously collected during drugging trials. Given that SpO2 remained at 97% dur-
ing apnoea, we hypothesized that increasing cerebral [ΔHHb] was a result of venous congestion as 
opposed to decreased oxygen delivery. Changes in heart rate were limited and appeared to be 
driven by the individual pharmacological actions of each drug. Future research could include sim-
ultaneous measures of metabolic rate, such as the relative change in concentration of cytochrome-
c-oxidase, to guide operators in determining when apnoea should be considered prolonged if 
changes in [ΔHHb] and [ΔO2Hb] occur beyond the limits recorded in this study. Our findings sup-
port the use of NIRS as real-time physiological monitoring tool during pinniped chemical immobi-
lisation, which could assist veterinarians and researchers in performing safe anaesthetic procedures. 
Keywords: phocid seals; near-infrared spectroscopy; cerebral haemodynamics; midazolam;  
ketamine; heart rate; haemoglobin saturation 
 
1. Introduction 
Handling animals is essential for many applications in wildlife research. Over the 
past several decades, research into pinniped (seals, sea lions, fur seals, and walruses) be-
haviour and physiology has increased markedly, and many studies require wild and cap-
tive animals to be safely captured or handled. For example, the deployment of electronic 
animal-borne tags to study animal movements and dive behaviour has now become 
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commonplace; between 1965 and 2013, tag data were used in 545 scientific papers which 
equates to the handling of several thousand wild pinnipeds around the world [1]. Simi-
larly, a number of long term pinniped behaviour and life history studies have involved 
the repeated capture and sampling of several thousand individuals over their lifetimes 
(e.g., den Heyer and Bowen 2017 [1]). The increased usage of chemical immobilisation in 
pinnipeds requires an understanding of the pharmacology of anaesthetic agents in pinni-
ped species and safe drugging procedures, which overcome potential challenges faced by 
anaesthetising these animals. 
Pinnipeds are medium- to large-sized animals that are potentially dangerous and re-
quire expert handling in order to maximise welfare and safeguard both animals and han-
dlers [2]. As such, sedation and anaesthesia are common practice in pinniped husbandry, 
medicine, and research [3]. Despite being relatively routine procedures for many species, 
there are elevated risks associated with anaesthesia and sedation for pinnipeds. For ex-
ample, pinnipeds are episodic breathers and terminal apnoea is a potential risk during 
anaesthesia [4–6]. Previous work with anaesthetic agents have produced highly variable 
results, including mortalities, as chemical compounds and administration procedures 
were adapted to the idiosyncrasies of these species [3,7]. Nevertheless, efficient protocols 
for both gas and injection anaesthesia in pinnipeds do now exist [3,8–11]. Injectable an-
aesthetics can be administered intramuscularly or intravenously. There are many injecta-
ble anaesthetic drugs suitable for use in pinnipeds; these include combinations of a disso-
ciative anaesthetic (e.g., ketamine and tiletamine) and a sedative (e.g., diazepam, midazo-
lam, and zolazepam). Gas anaesthesia is typically used to maintain prolonged immobili-
sation or to achieve a surgical plane of anaesthesia in pinnipeds and common agents in-
clude halothane, sevoflurane, and isoflurane [3,9]. 
The appropriate anaesthetic procedure depends on the drugging scenario (e.g., con-
ditions in the field vs. in captivity, the plane and duration of anaesthesia needed for a 
given experimental set-up or medical procedure, and the species being anaesthetised, etc.) 
[3,8,9]. Ketamine is widely used in veterinary practices for large animals and is the most 
common anaesthetic agent for pinnipeds [3,12]. It provides a rapid induction and recovery 
from anaesthesia with a wide margin of safety as it preserves respiratory and cardiac func-
tion at small doses [13]. Ketamine stimulates the sympathetic nervous system and cardio-
vascular system, causing the presentation of a dissociative state, which is characterised by 
a lack of responsive awareness. [12]. The most frequently reported adverse effect of keta-
mine on pinnipeds is muscular quivering and tremors [9,10,14]. As such, ketamine is now 
generally used in combination with sedatives providing muscle-relaxant properties such 
as midazolam [3,9,10]. 
Midazolam is a benzodiazepine, which is a class of drug that causes neural inhibition 
throughout the central nervous system [15,16]. While they are generally considered to 
have minimal effects on cardiovascular systems, benzodiazepines may decrease systemic 
vascular resistance, cause a moderate decline in arterial blood pressure, and increase heart 
rate [15]. In pinnipeds, benzodiazepines are generally used with a high margin of safety 
[3]. While ketamine was once frequently combined with diazepam, midazolam, which is 
more recently available, is now the preferred alternative for pinnipeds due to its high sol-
ubility and rapid onset of action [9]. 
Despite the wide margins of safety in current procedures for pinniped chemical im-
mobilisation, results from previous studies have shown a high variability in individual 
response to routine anaesthetic agents [3,17,18]. Given the uncertainty in physiological 
responses to drugging, various antagonists have been used in an attempt to improve the 
safety of anaesthetic procedures for pinnipeds. Doxapram, yohimbine, flumazenil, and 
atipamezole are some examples of antagonists, which have been employed for emergency 
resuscitation or to decrease recovery times from pinniped anaesthesia [9,10].  
Importantly, seals have an accentuated “dive response” upon submersion under wa-
ter and the inhibition of respiration [19]. While all air-breathing vertebrates exhibit the 
dive response, diving marine mammals, including pinnipeds, have developed specialised 
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anatomical and physiological adaptations to withstand longer periods of submersion at 
depth. Elephant seals, for example, can dive to depths beyond a kilometre [20] for as long 
as 2 h [21,22]. In pinnipeds, the dive response activates nervous system activity and is 
characterised by the rapid onset of pronounced bradycardia (i.e., reduction in heart rate) 
and peripheral arterial constriction [23]. The resulting decrease in cardiac output and in-
crease in peripheral resistance causes a major redistribution of blood to high-priority tis-
sues, especially the brain [24]. Major circulatory changes and extended periods of apnoea 
likely means that pinnipeds exhibit a unique set of responses under chemical immobilisa-
tion [3]. Further, previous research has provided evidence for some level of cognitive con-
trol of the dive response in California sea lions (Zalophus californianus) [25], harbour por-
poises (Phocoena phocoena) [26], bottlenose dolphins (Tursiops truncatus) [27], and harbour 
seals (Phoca vitulina) [4,5]. For example, a study conducted by McKnight et al., 2019 ap-
plied wearable near-infrared spectroscopy (NIRS) technology to voluntarily diving har-
bour seals in order to investigate resulting haemodynamic changes in the blubber and 
brain [5]. Their results showed that circulatory changes of the dive response occurred in 
advance of submersion under water and surfacing. These findings [4,5,25–27] indicate that 
the assumed autonomic system of diving mammals is influenced by cognitive input.  
The use of drugs, which impact cognitive performance, may therefore render the 
maintenance of physiological parameters vulnerable in pinnipeds, especially when these 
mechanisms of control are, in-part, cognitive as well as autonomic. As a result, safe chem-
ical immobilisation procedures require careful real-time monitoring to prevent overdos-
age and to avoid the need for intubation during extended apnoea. In pinnipeds, the plane 
of anaesthesia is typically inferred through observation of basic responses and subtle body 
movements [9]. Current methods used to monitor physiological status during pinniped 
chemical immobilisation procedures include monitoring heart rate and respiratory rate, 
pulse oximetry and/or capnography for monitoring ventilation, mucous membrane colour 
to monitor oxygenation, and using rectal temperature probes to measure body tempera-
ture [9]. Although the appropriate maintenance of brain oxygenation is one of the most 
important factors for physiological homeostasis under anaesthesia, the brain is one of the 
least monitored organs during anaesthesia, even in humans [28]. This paucity of infor-
mation is derived, in part by a lack of suitable technologies for making accurate real-time 
measurements of cerebral oxygenation. Wearable NIRS technology offers a potential re-
search tool with which to study and monitor the physiological responses, including cere-
bral oxygenation, of pinniped species to chemical immobilisation.  
NIRS is an optical imaging method that measures light absorbance through biologic 
tissues in the near-infrared spectral window (750–1000 nm) [29]. NIRS devices operate by 
emitting specific wavelengths of near-infrared light from a light-emitting optode, that cor-
respond to the absorption spectra of cerebral chromophores: oxygenated haemoglobin, 
deoxygenated haemoglobin, and oxidised cytochrome-c-oxidase. The oxygenation status 
of these compounds determines the wavelengths of near-infrared light that they absorb. 
Scattered light, which is not absorbed by chromophores, is detected by photodiode receiv-
ers/optodes. The NIRS system then translates the loss of light intensity into measurements 
of relative change in concentration of the targeted chromophores. These measurements 
act as proxies for several other important physiological parameters, including cerebral 
blood perfusion, cerebral oxygenation, heart rate, breathing rate, proxies of blood pres-
sure changes, oxygen consumption, and arterial oxygen saturation [29]. Considering the 
paucity of information on physiological responses of pinnipeds to anaesthesia, the appli-
cation of this technology could elucidate the effects of anaesthetic agents on brain haemo-
globin oxygenation in pinnipeds and could provide real-time physiological monitoring 
during chemical immobilisation procedures.  
This study used existing continuous-wave, spatially resolved NIRS [30] data from 
ten trials of prolonged anaesthesia induced in five grey seals (Halichoerus grypus) due to 
their involvement in other experimental procedures. The injectable anaesthetic agents, 
ketamine and midazolam, were used to induce and maintain anaesthesia. NIRS 
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measurements were taken from an array of optical sensors that were fitted to a customised 
neoprene cap placed on the head of each seal. The aims of this study were to (1) charac-
terise the effect of each drug on heart rate, arterial oxygen saturation (SpO2), and cerebral 
haemoglobin oxygenation as measures of systemic changes to physiological homeostasis 
and (2) to investigate the use of NIRS as a real-time physiological monitoring tool during 
chemical immobilisation.  
2. Materials and Methods 
2.1. Ethics Statement 
Procedures for capture, handling, and housing of animals conformed to the Animals 
(Scientific Procedures) Act 1986, under the Sea Mammal Research Units’ Home Office li-
cence (#70/7806). 
2.2. Experimental Methods 
Five juvenile grey seals (1 female and 4 males) were captured in the Moray Firth, 
Scotland and were temporarily housed at the Sea Mammal Research Unit (SMRU) for a 
Natural Environment Research Council funded study on the impacts of pollutants on fat 
tissue function (see Supplementary Tables S1 and S2 for capture dates and morphometric 
data, respectively). The captured seals were taking part in a series of experiments; two of 
which provided the data used in the current study. One study involved measuring cere-
bral activation in response to a series of acoustic, visual, and tactile stimuli [31]. The other 
study involved measuring the relationship between tissue oxygenation, blubber depth, 
and fatness [32].  
2.2.1. Drugging Procedure  
All seals were fasted overnight (approximately 12–18 h) before the experimental and 
chemical immobilisation procedures. Prior to experimentation, seals were captured and 
handled in a pup bag to administer 4.0 mL of midazolam (Hypnovel, Roche Products Ltd., 
Welwyn Garden City, UK; 5 mg/mL solution) intramuscularly as a premedication seda-
tive. They were left in isolation for 10 min for the sedative to take effect. Seals were then 
re-captured to administer 1 mg/kg ketamine (Ketamidor, Chanelle Pharma, Loughrea, 
UK; 100 mg/mL solution) intravenously to induce anaesthesia. A further ketamine dose 
was administered if excessive movements were apparent. Once individuals were ob-
served under a suitable plane of anaesthesia, they were moved into an indoor lab for the 
experimental trials.  
Intermittently, throughout the experimental trials 0.25–0.5 mL of Ketamidor doses 
were administered intravenously to maintain immobilisation and 1.0 mL of Hypnovel 
doses were administered intravenously to control muscle tremors. The number and fre-
quency of doses that were given during each experimental trial was dependent on the 
seals’ individual responses to the drugs, with the exception of the initial intramuscular 
dose of midazolam, which was constant across all individuals. The drugging procedure 
utilised here is bespoke for prolonged anaesthesia in seals only. The drugging procedure, 
necessary for prolonged maintenance of an adequate plane of anaesthesia for the studies 
described in Section 2.2., has been developed to safely manage seals with a structured 
balance of an anaesthetic agent (ketamine) and a sedative (midazolam) across time. 
2.2.2. Instrumentation 
For each experimental trial, the seals were fitted with a customised neoprene cap 
containing an optode array that was connected to the near-infrared spectroscopy device 
(‘Brite24′ Artinis Medical Systems BV, Einsteinweg, The Netherlands), which was meas-
uring changes in light intensity at a sampling frequency of 10 Hz. The customised head 
cap was developed using 3D photogrammetry software (Photomodeler Scanner 2016, 
Photomodeler Technologies, Vancouver, Canada) to create a computational model of a 
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juvenile grey seal head [31]. Once completed, the head cap was fitted to the head of a 
freshly dead juvenile grey seal and 3D photogrammetry software was then used to create 
a model of the seal’s head that incorporated the optode/detector locations so that the cer-
ebral locations of NIRS signals could be interpreted in analysis [31]. For further detail on 
neoprene cap design and attachment methods see McKnight et al., 2021 [31].  
The optode/detector array consisted of 8 photodiode detectors and 16 LED dual-
wavelength emitters. Each emitter provided two near-infrared light sources with wave-
lengths of 755–758 nm and 839–854 nm. The optode/detector array provided 28 channels, 
of which 20 had an optode-detector separation distance of around 30 mm (long channels), 
which were sensitive to the brain and superficial layers (scalp and skull). The remaining 
8 channels had an optode-detector distance of around 10 mm (short channels) and were 
only sensitive to the superficial layers. Short channels are typically used to filter out sig-
nals from the superficial layers to isolate the cerebral haemodynamic response signals 
needed for functional NIRS analysis. An area of hair (10 mm diameter) was cut from each 
optode location using handheld clippers to prevent interference with NIRS signals during 
experimental trials.  
Measured changes in light intensity were automatically converted to measurements 
of relative change in concentration of oxygenated [ΔO2Hb] and deoxygenated haemoglo-
bin [ΔHHb] within the NIRS control software; Oxysoft (Version 3.2.51.2, Artinis Medical 
Systems BV, Einsteinweg, The Netherlands). Both [ΔO2Hb] and [ΔHHb] measurements 
were made using the modified Beer-Lambert law, which describes tissue optical absorp-
tion, assuming constant scattering [33,34]. For each experimental trial, individual respira-
tions were also measured using a respiratory band (‘FLOW’, Sweetzpot, Oslo, Norway), 
which was secured around their chest. The respiratory band data were collected at a sam-
pling frequency of 10 Hz. 
2.2.3. Data Collection 
Data used for analysis was gathered as part of two separate experiments. The first 
series of experiments (n = 10) were conducted in November of 2018 [31]. After initial drug-
ging and instrument fitting, individual seals were exposed to visual, auditory, and tactile 
stimuli. Each seal underwent this experimental procedure twice. The second series of ex-
periments (n = 5) were conducted in November and December of 2018 [32]. In each exper-
imental trial, the customised neoprene head cap was used to measure [ΔO2Hb] and 
[ΔHHb] in the brain opportunistically while other physiological parameters were simul-
taneously measured. Each seal underwent this experimental procedure once.  
These two studies resulted in 15 experimental trials using chemical immobilisation 
and NIRS to measure oxygenation changes in the brain. It was not possible to conduct 
control trials in which animals were not anaesthetised, given that instrument attachment 
required animals to remain motionless. For both experimental procedures, each trial was 
filmed using a mounted GoPro 4 White (Clearview Way, San Mateo, CA, USA) once indi-
viduals were moved to the indoor lab. Therefore, the initial intramuscular dose of mid-
azolam was not recorded for any of the trials. Since the onset of action for both ketamine 
and midazolam occurs within seconds [13,15,35], times associated with each administra-
tion were recorded to the closest second. These were extracted from visually inspecting 
video footage and were inserted as labels within their respective experimental trials in 
Oxysoft. However, during five of the trials, the camera view around the timing of the ad-
ministrations was intermittently obstructed by personnel; in those cases, the experimental 
trial was excluded from further analyses. Of the remaining 10 trials used for analysis, two 
midazolam and six ketamine administrations were not included in analysis for the same 
reason. Further, from the five seals included in experimentation, only four provided visi-
ble midazolam administrations, which were used in analysis. In total, 32 ketamine admin-
istrations (Marvin: 11, L’Hollie: 5, Haans: 3, Gruber: 6, Jones: 7) and 11 midazolam admin-
istrations (Marvin: 1, L’Hollie: 2, Gruber: 6, Jones: 2) were taken forward to data extrac-
tion. 
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2.3. Data Extraction 
To measure the variation in brain oxygenation and its physiological drivers in re-
sponse to drugging events, a series of post hoc modelling approaches were undertaken. 
[ΔO2Hb], [ΔHHb], heart rate, and SpO2 were extracted as dependent variables resulting 
in four separate responses to both ketamine and midazolam. The respiratory band data 
were additionally extracted to be included as an independent variable for model selection 
and to count the mean number of breaths throughout drugging trials. [ΔO2Hb] and 
[ΔHHb] were chosen for analysis to assess whether essential cerebral oxygenation and 
blood volume were maintained during chemical immobilisation. Heart rate and SpO2 
were analysed as they are informative physiological parameters of systemic cardiorespir-
atory changes. Further, these two parameters are commonly monitored during pinniped 
anaesthesia and allow for comparison with other studies. 
2.3.1. Extraction of Haemodynamic Variables ([ΔO2Hb] and [ΔHHb]) 
Drugging times were incorporated into Oxysoft and measurements of [ΔO2Hb] and 
[ΔHHb] (μ mol L−1) were extracted to Microsoft Excel (Version 16.43, Microsoft Corpora-
tion, Redmond, WA, USA) to construct data tables for modelling. For each ketamine and 
midazolam administration, 5 min pre-administration to 5 min post-administration of 
[ΔO2Hb] and [ΔHHb] measurements were extracted for one long channel in the left hem-
isphere of the brain and one long channel in the right hemisphere (Figure 1). The channels 
shown in Figure 1 were chosen as they represented the shallowest skin-cortical tissue 
paths. Given that the onset of action for both ketamine and midazolam occurs within 1 
min of intravenous administration [13,15,35], the 10 min time frame was extracted to pro-
vide a buffer period within which physiological changes would be captured. For the pur-
pose of this study, short channels receiving NIRS signals from superficial layers were not 
subtracted from long channels because we were analysing systemic level changes. There-
fore, it was not necessary to eliminate systemic interference of the superficial layers, espe-
cially given that the magnitude of systemic changes is not significantly affected by con-
tamination from extracerebral signals.  
 
Figure 1. The optode array configuration overlaid on the head of a juvenile grey seal for anatomical 
perspective of the light emitter (red points) and detector (black points) locations. Black lines indicate 
each of twenty 3 cm optode-detector distance channels and green circles indicate the two channels 
that were chosen for analysis, which are found between the parietal and pre-frontal lobe. 
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Once measurements were extracted, they were compiled into two data tables: one for 
all ketamine administrations and one for all midazolam administrations. A drug admin-
istration and its analysis time window is referred to as a ‘drugging trial’ for the purpose 
of this paper. For each drugging trial, the animal ID, side (left or right hemisphere), cu-
mulative bolus volume of both midazolam and ketamine at time of administration (mL), 
bolus volume of either ketamine or midazolam at time of administration (mL), and time 
since initial drugging of ketamine or midazolam (s) were compiled as independent varia-
bles in the models.  
 Exploratory plots revealed that oxygenation responses were apparent up to 3 min 
post-administration and that 1 min pre-administration was sufficient time to provide a 
baseline to compare the response to. Therefore, the data were restricted to 60 s pre-admin-
istration and 180 s post-administration. All further analyses were conducted on this re-
stricted dataset and for the purpose of this paper, time (s) as an independent variable with 
respect to modelling refers to the 60 s pre- to 180 s post-administration analysis window.  
The exploratory plots were also used to identify potential outliers of concentration 
measurements that occurred outside the physiological limits of these animals. Since we 
analysed systemic changes in [ΔO2Hb] and [ΔHHb], physiological signals such as heart 
rate and breathing contributed to measured systemic changes [29]. Breathing, in particu-
lar, may induce marked changes in [ΔO2Hb] up to 20 μ mol L−1 within a frequency band-
width of 0.2 to 0.6 Hz. If changes in [ΔO2Hb] and [ΔHHb] occurred at a greater magnitude, 
those signals were more likely a result of motion artefacts, such as cap re-adjustment, and 
were removed from analysis. Similarly, if outliers in [ΔO2Hb] did not present regular car-
diac pulsations, they were more likely disrupted signals and were removed from analysis. 
For three ketamine drugging trials and four midazolam drugging trials, the analysis win-
dows were therefore cut to less than 60 s pre-administration and 180 s post-administra-
tion. Another four ketamine drugging trials were completely removed from analysis un-
der the same reasoning. Additionally, two ketamine drugging trials were administered 9 
s in succession and therefore one of these trials was removed from analysis to prevent 
pseudoreplication (see Supplementary Table S3 for the distribution of the number of usa-
ble drugging trials across individual seals). 
Measures of total haemoglobin ([ΔtHb] = [ΔO2Hb] + [ΔHHb]) and relative haemoglo-
bin difference ([ΔHbdiff] = [ΔO2Hb] − [ΔHHb]) were also added to the data table for anal-
ysis. [ΔtHb] was used as a proxy for relative cerebral blood volume changes and [ΔHbdiff] 
was used as a measure of relative haemoglobin oxygenation changes. These parameters 
were added to the raw data plots (see Results) to quantify what the magnitudes of change 
in [ΔO2Hb] and [ΔHHb] mean for overall cerebral blood volume and oxygenation 
changes. 
2.3.2. Extraction of Respiratory Data 
The respiratory band data were included as independent variables in analysis to ac-
count for the associated systemic changes in haemoglobin concentration on cerebral oxy-
genation. Additionally, changes in intrathoracic pressure during respiration affect heart 
rate [36]. During inhalation, the decrease in intrathoracic pressure increases venous return 
stimulating atrial stretch receptors and causing increased heart rate (Bainbridge reflex). 
The converse occurs during exhalation (Reverse Bainbridge reflex).  
To add respiratory band measurements as a variable for analysis, we needed to cor-
rect the drift in the respiratory band impedance measures. A generalised additive model 
(GAM) was created for each drugging trial of the respiratory band data in RStudio (Ver-
sion 1.2.1335, RStudio PBC, Boston, MA, USA) using the “gam” function of the “mgcv” 
package (Version 1.8–31). The respiratory band data were fitted within each model and 
the residuals were subtracted to isolate the original values and reverse the effect of the 
drift over time. The corrected respiratory band data were then extracted and added to the 
corresponding time frame of each drugging trial.  
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The respiratory band data were further used to count the number of breaths in each 
drugging trial to assess whether our drugging methodology affected breathing patterns 
of the anaesthetised seals. Seals on land and during diving show a similar pattern of epi-
sodic breathing, characterised by infrequent periods of rapid deep breaths in between 
longer periods of apnoea. In captive freely diving grey seals, the average respiratory rate 
at the surface was 19 breaths min−1 occurring between average dive durations of around 
4 min [37]. To derive breathing rates in our study, the raw and corrected respiratory band 
data were plotted for each drugging trial and the number of breaths were counted by the 
maxima (inspiration) or minima (expiration) of voltage magnitude changes that extended 
beyond the baseline voltage variability of the respiratory band. Additionally, [ΔO2Hb] for 
each channel of the optode/detector array was simultaneously plotted for each corre-
sponding drugging trial to verify that the identified patterns of breathing were reflected 
in the NIRS measurements. The mean number of breaths were calculated in 30 s intervals 
of each drugging trial and were included in the Results independent of statistical model-
ling.  
2.3.3. Heart Rate Extraction 
The method for heart rate extraction used here is described in detail in [38]. In short, 
heart rate was extracted from NIRS measurements using the heart rate derivation algo-
rithm presented in [39]. The first step of the algorithm is the pre-processing step in which 
systemic artefacts, motion artefacts, and other unrelated frequency components were re-
moved from the NIRS signal through the use of a 100th order zero-phase bandpass FIR 
filter between 0.1 Hz and 4 Hz. In the second step, heart rate was extracted by applying 
the AMPD method [40] for the detection of peak points in the pre-processed signal. The 
final step of the derivation algorithm is the correction process in which a window method 
[39] was used to reduce errors in peak detection. Extracted heart rate data were added to 
the corresponding time scale for each drugging trial in beats per minute (BPM). 
2.3.4. Arterial Oxygen Saturation (SpO2) Extraction 
The SpO2 extraction process was performed in MATLAB (Version 9.9.0.1495850 
[R2020b], The MathWorks Inc., Natick, MA, USA) based on methods used in Menssen et 
al., 2009 [41]. First, a highpass 3rd order zero-phase Butterworth filter with a cut-off fre-
quency at 0.4 Hz was applied to the [ΔO2Hb] and [ΔHHb] measurements. The filtered 
[ΔO2Hb] and [ΔHHb] measurements were used to create frequency spectrograms show-
ing heart rate variation across the analysis windows. To generate these spectrograms, fast 
Fourier transforms (FFTs) were calculated. The FFT window size was dependent on the 
variation in heart rate within each drugging trial (mean: 32 s, range: 16–40 s) and the FFT 
overlap was always 90%. The spectral power of [ΔO2Hb] and [ΔHHb] at the most promi-
nent frequency component was extracted as this was identified as the heart rate at any 
given time point within the spectrogram. Using the extracted values of spectral power, 
SpO2 was calculated as SpO2 = [ΔO2Hbp] / ([ΔO2Hbp] + [ΔHHbp]) for each time point. Once 
extracted, SpO2 measurements and their respective time stamps were synchronised with 
the existing data frames containing the remaining variables for analysis. 
2.4. Statistical Modelling  
The average group response to ketamine and midazolam was modelled using gener-
alised additive mixed models (GAMM) for each dependent variable: [ΔO2Hb], [ΔHHb], 
heart rate, and SpO2. GAMMs were chosen for analysis due to their flexibility in capturing 
non-linear changes in the physiological responses to drugging and for their ability to in-
corporate random effects, which account for individual variation. All data analyses were 
completed in RStudio (Version 1.2.1335) and the “gamm” function of the “mgcv” package 
(Version 1.8–31) was used to construct GAMMs.  
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Models for [ΔO2Hb], [ΔHHb], and heart rate were constructed using 27 trials of ket-
amine administration and 11 trials of midazolam administration. Haemodynamic signals 
were originally collected at a sampling frequency of 10 Hz to extract heart rate. However, 
ketamine and midazolam exert their pharmacological effects in a matter of seconds, mean-
ing it was not necessary to analyse a sub-second response in [ΔHHb], [ΔO2Hb], and heart 
rate following drugging. To improve processing efficiency the dataset was reduced to a 
sampling frequency of 2 Hz for the [ΔO2Hb], [ΔHHb], and heart rate models. The reduc-
tion in sampling frequency was only completed following heart rate and SpO2 extraction 
for the purpose of statistical modelling 
The SpO2 extraction relied upon wider sampling windows to generate an SpO2 esti-
mate, meaning SpO2 analysis was more sensitive to motion artefacts than the instantane-
ous measures of heart rate. Therefore, four ketamine drugging trials and two midazolam 
drugging trials were removed from SpO2 analysis during the extraction process because 
we were unable to identify reliable measurements of heart rate. The number of FFTs that 
were calculated (i.e., the frequency spectrogram window size and overlap) during SpO2 
extraction limited the number of SpO2 measurements that were calculated and extracted. 
As such, the SpO2 dataset was not reduced further for statistical modelling. 
The independent variables used in model selection are presented in Table 1. Time 
since initial drugging and bolus volumes were included to account for the magnitude of 
response based on how much of either compound was already present and how long the 
animal had been under anaesthesia. The bolus volumes for midazolam consisted of doses 
5 mL, 6 mL, 7 mL, 8 mL, and 9 mL. When this variable was included as a smooth function 
the models would not run due to limited variation in the data. Therefore, midazolam bo-
lus volume was included as a factor variable.  
Table 1. The independent variables included in the model selection process for the response in 
[ΔO2Hb], [ΔHHb], heart rate, and SpO2 to ketamine and midazolam administration. For each inde-
pendent variable, the variable type (smooth function, factor variable, or random effect) and the de-
pendent variable and drug for which it was included in model selection is presented. 
Variable Variable Type Dependent Variable Drug 
Time series starting at 60 
s pre-drugging to 180 s 
post-drugging 
Smooth 
[ΔO2Hb], [ΔHHb], heart 
rate, and SpO2 
Ketamine and  
midazolam 
Time since initial drug-
ging (s) 
Smooth 
[ΔO2Hb], [ΔHHb], heart 
rate, and SpO2 
Ketamine and  
midazolam 
Cumulative bolus volume 
of ketamine and midazo-
lam (mL) 
Smooth  
[ΔO2Hb], [ΔHHb], heart 
rate, and SpO2 
Ketamine and  
midazolam 
Respiratory band (mV) Smooth 
[ΔO2Hb], [ΔHHb], and 
heart rate 
Ketamine and  
midazolam 
Ketamine bolus volume 
(mL) 
Smooth 
[ΔO2Hb], [ΔHHb], heart 
rate, and SpO2 
Ketamine 
Midazolam bolus volume 
(mL) 
Factor 
[ΔO2Hb], [ΔHHb], heart 
rate, and SpO2 
Midazolam 
Side (left or right hemi-
sphere) 
Factor  [ΔO2Hb] and [ΔHHb] 
Ketamine and  
midazolam 
Animal ID Random effect 
[ΔO2Hb], [ΔHHb], heart 
rate, and SpO2 
Ketamine and  
midazolam 
The cumulative bolus volume of ketamine and midazolam was used to account for 
the potential additive effect of the two drugs in combination. The effect of either drug on 
the other was not accounted for by the use of an interaction term because the aim of our 
study was not to disentangle the isolated effect of each drug but rather to characterise the 
response to a standardised drugging procedure.  
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The respiratory band data were included in [ΔO2Hb], [ΔHHb], and heart rate model 
selection to account for the effects of breathing on systemic changes in dependent varia-
bles. However, model selection for the response in SpO2 did not include the respiratory 
band data since the effects of breathing were accounted for and removed in the SpO2 ex-
traction process. 
The Side (left or right hemisphere) variable was included as a factor variable instead 
of an interaction term for [ΔO2Hb] and [ΔHHb] models, since the raw data showed a high 
degree of similarity between the haemodynamic signals of the two hemispheres. Despite 
this similarity, it was still included in model selection to avoid the assumption of a global 
haemodynamic response to drugging in the brain. The Side (left or right hemisphere) fac-
tor variable was not included in heart rate and SpO2 model selection, given that changes 
in heart rate and SpO2 are systemic and should not differ between the left and right hem-
ispheres of the brain. The animal ID was included as a random effect for all models to 
account for individual variation. 
Family selection included Gaussian, Gaussian with a log link, Gaussian with an iden-
tity link, gamma, gamma with a log link, tweedie, poisson, and quasipoisson families [42]. 
Dependent variables were transformed to positive values for families that require them 
(i.e., Gaussian with a log link). This transformation was completed by adding the magni-
tude of the minimum value for each dependent variable to their respective dataset. The 
family for each model was chosen based on inspection of normality and residual distribu-
tion in residual plots. Backward elimination model selection was conducted using Akaike 
Information Criterion (AIC) based on the protocol of the “mgcv” R package developer 
[42]. The model with the lowest AIC was chosen as the best fit model and model predic-
tions were plotted. An example code for model selection of the [ΔHHb] response to keta-
mine is presented in the supplementary materials. Model selection for SpO2 did not in-
clude family selection. Since SpO2 is the percentage of [ΔO2Hb] in [ΔtHb], the binomial 
family was chosen for SpO2 response models based on its ability to model proportions. 
Using the binomial family, the same process of backward elimination model selection was 
conducted and model predictions were plotted. All response models were initially run 
without a specification of knots, which resulted in overfitting. Therefore, the number of 
knots was specified as k=4 for all smooth terms within the haemodynamic, heart rate, and 
SpO2 response models for ketamine and midazolam to prevent overfitting.  
3. Results 
Responses to each drug were successfully measured for 27 extracted trials of keta-
mine administration and 11 trials of midazolam administration (see Supplementary Table 
S3 for the distribution of the number of drugging trials across individual seals). The neo-
prene head cap with integrated emitters and receivers of a NIRS system continuously 
measured [ΔHHb] and [ΔO2Hb] throughout experimentation. A suitable plane of anaes-
thesia was maintained throughout experimentation and all seals included in this study 
were left to emerge in a safe area and monitored to ensure smooth recovery following the 
experimental trials. Given that the drugging procedure required an initial midazolam and 
ketamine drugging to induce anaesthesia, neither drug was tested in isolation and within 
each drugging trial the animals were under the influence to varying degrees of both drugs 
(See Supplementary Figure S1 for raw measurements of four drugging trials administered 
in succession). Therefore, the 60 s pre-administration baseline within each drugging trial 
is not representative of a normal resting state and may differ between trials. Observed 
patterns in the raw data were reflected in the modelled data for [ΔHHb], [ΔO2Hb], heart 
rate, and SpO2. 
  




3.1.1. Raw Data 
[HHb] increased following ketamine administration (Figure 2A,B; pre-administra-
tion mean: −0.3 μ mol L−1 and range: −0.5 to 0.02 μ mol L−1, post-administration mean: 1.4 
μ mol L−1 and range: −0.3 to 4.1 μ mol L−1), whereas [ΔO2Hb] decreased (Figure 2A,B; pre-
administration mean: 0.9 μ mol L−1 and range: −0.7 to 2.9 μ mol L−1, post-administration 
mean: −1.9 μ mol L−1 and range: −4.3 to 1.8 μ mol L−1). [ΔtHb] was initially decreasing and 
then increased following ketamine administration (Figure 2A,B; pre-administration mean: 
0.6 μ mol L−1 and range: −1.0 to 2.6 μ mol L−1, post-administration mean: −0.4 μ mol L−1 
and range: −2.2 to 2.5 μ mol L−1). [ΔHbdiff] decreased following ketamine administration 
(Figure 2A,B; pre-administration mean: 1.1 μ mol L−1 and range: −0.7 to 3.2 μ mol L−1, post-
administration mean: −3.3 μ mol L−1 and range: −8.2 to 1.5 μ mol L−1). The left and right 
hemispheres (Figure 2A,B) showed the same trends for the haemodynamic variables with 
marginal differences in exact values of measurements. Heart rate was variable throughout 
the analysed time frame, although heart rate variation decreased following ketamine ad-
ministration (Figure 2C; pre-administration mean: 95.8 BPM and range: 72.4 to 117.9 BPM, 
post-administration mean: 78.3 BPM and range: 58.6 to 107.5 BPM). Additionally, heart 
rate generally decreased following ketamine administration. SpO2 remained high 
throughout the analysis window (Figure 2D; pre-administration mean: 97.8% and range: 
94.4 to 99.4%, post-administration mean: 98.3% and range: 94.1 to 99.8%).  




Figure 2. Example of cerebral haemodynamics and global systemic changes for 60 s before and 180 s after ketamine ad-
ministration at time 0 s for one drugging trial. Cerebral haemodynamics include [ΔHHb] (μ mol L−1), [ΔO2Hb] (μ mol L−1), 
relative cerebral blood volume changes [ΔtHb] (μ mol L−1), and relative haemoglobin oxygenation changes [ΔHbdiff] (μ 
mol L−1) in the (A) left and (B) right hemispheres of the brain. Systemic changes include (C) heart rate (BPM) and (D) SpO2 
(%). All concentrations are expressed as relative changes from a baseline (0 μ mol L−1) at time of drug administration. This 
ketamine drugging trial was taken from Jones on 06 December 2018 and was preceded by an initial intramuscular dose of 
midazolam and five intravenous ketamine doses. For combined raw data for all ketamine drugging trials see Supplemen-
tary Figures S2 and S3. [ΔHHb], change in concentration of deoxygenated haemoglobin; [ΔO2Hb], change in concentration 
of oxygenated haemoglobin; [ΔtHb], change in concentration of total haemoglobin; [ΔHbdiff], difference in concentration 
of oxygenated and deoxygenated haemoglobin; SpO2, arterial oxygen saturation. 
3.1.2. Model Results 
The model prediction plot for the response to ketamine showed a decrease in [ΔHHb] 
prior to ketamine administration (Figure 3). [ΔHHb] continued to decrease until approxi-
mately 20 s, after which there was a marked increase in [ΔHHb] that continued until 180 
s. The model prediction plot for the response in [ΔO2Hb] to ketamine showed an increase 
in [ΔO2Hb] prior to administration (Figure 3). This increase continued until approximately 
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30 s after ketamine administration. [ΔO2Hb] then decreased and became relatively con-
stant at approximately 120 s with a negative [ΔO2Hb] of around −0.6 μ mol L−1. Overall, 
the response in [ΔO2Hb] occurred at a lower magnitude of change in comparison to 
[ΔHHb]. The left (Figure 3A) and right (Figure 3B) hemispheres showed the same trends 
for the haemodynamic variables with marginal differences in exact values of measure-
ments.  
 
Figure 3. GAMM model prediction outcomes for [ΔHHb] (μ mol L−1), [ΔO2Hb] (μ mol L−1), and heart 
rate (BPM) in the (A) left hemisphere and (B) right hemisphere for 60 s before and 180 s after keta-
mine administration at time 0 s for 27 trials across five grey seals. For illustrative purposes a baseline 
shift was completed so that all concentrations are expressed as relative changes from a baseline (0 μ 
mol L−1) between the left and right hemispheres at time of drug administration. Changes in heart 
rate are systemic, meaning the presented model prediction outcomes for heart rate are the same for 
the left and right hemispheres. The shaded regions represent the 95% confidence intervals. GAMM, 
generalised additive mixed model; [ΔHHb], change in concentration of deoxygenated haemoglobin; 
[ΔO2Hb], change in concentration of oxygenated haemoglobin. 
The predicted mean heart rate was relatively stable at around 75 BPM before keta-
mine administration (Figure 3). Following ketamine administration, heart rate initially de-
creased until approximately 110 s, after which it increased until the end of the analysis 
window. The changes in heart rate were relatively small, with predicted mean values 
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between 70.6 and 75.5 BPM. The model predictions for the responses in SpO2 to ketamine 
administration remained relatively stable with a range of 97.6 to 97.9% (Supplementary 
Figure S4).  
The [ΔHHb] response to ketamine was modelled assuming errors with a Gaussian 
log link distribution. The model with the lowest AIC retained all variables except the res-
piratory band (Equation (1) in the Supplementary Materials, Supplementary Table S4). 
The response of [ΔO2Hb] to ketamine was modelled assuming errors with a Gaussian 
identity link distribution. For the [ΔO2Hb] model, all covariates were retained (Equation 
(2) in the Supplementary Materials, Supplementary Table S4). The response in heart rate 
to ketamine was modelled assuming errors with a Gaussian log link distribution. All co-
variates included in heart rate model selection were retained in the model with the lowest 
AIC (Equation (3) in the Supplementary Materials, Supplementary Table S4). The bino-
mial family was used to model the response of SpO2 and the model with the lowest AIC 
retained all variables included in model selection except the time since initial drugging 
(Equation (4) in the Supplementary Materials, Supplementary Table S4). For model out-
puts of each response model see Supplementary Tables S5–S8. 
3.1.3. Breathing Rates 
The mean number of breaths over the 4 min analysis window of ketamine drugging 
trials was 11.5. Breathing was episodic throughout the analysed drugging trials as evi-
denced in the quartile ranges for the mean number of breaths in 30 s intervals presented 
in Figure 4. In Figure 4, the highest mean number of breaths occurred within 30 s before 
ketamine administration, after which the number of breaths decreased. The episodic na-
ture of breathing was characterised, in part, by periods of hyperventilation, which typi-
cally occurred before ketamine administration and within 60 s after administration.  
 
Figure 4. The mean number of breaths in 30 s intervals for 60 s before and 180 s after ketamine 
administration at time 0 s for 27 trials across five grey seals. Error bars represent the upper (75th 
percentile) and lower (25th percentile) quartile range of the data. 
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3.2. Midazolam  
3.2.1. Raw Data 
Following midazolam administration [HHb] increased (Figure 5A,B; pre-administra-
tion mean: 0.2 μ mol L−1 and range: −0.8 to 2.7 μ mol L−1, post-administration mean: 1.8 μ 
mol L−1 and range: −0.01 to 3.9 μ mol L−1). [ΔO2Hb] initially showed a marginal decrease 
following midazolam administration and then increased towards the end of the analysis 
window (Figure 5A,B; pre-administration mean: 0.2 μ mol L−1 and range: −1.3 to 1.3 μ mol 
L−1, post-administration mean: −0.6 μ mol L−1 and range: −2.2 to 1.6 μ mol L−1). There was 
an overall increase in [ΔtHb] following midazolam administration (Figure 5A,B; pre-ad-
ministration mean: 0.4 μ mol L−1 and range: −2.0 to 3.6 μ mol L−1, post-administration 
mean: 1.2 μ mol L−1 and range: −0.7 to 4.7 μ mol L−1) with a concomitant decrease in [ΔHb-
diff] (Figure 5A,B; pre-administration mean: 0.04 μ mol L−1 and range: −1.8 to 1.1 μ mol L−1, 
post-administration mean: −2.5 μ mol L−1 and range: −5.1 to 0.2 μ mol L−1). The left and 
right hemispheres showed the same trends for the haemodynamic variables with mar-
ginal differences in exact values of measurements (Figure 5A,B). Heart rate was variable 
throughout the analysis window and showed a marginal decrease following midazolam 
administration (Figure 5C; pre-administration mean: 83.2 BPM and range: 58.0 to 111.0 
BPM, post-administration mean: 71.5 BPM and range: 50.0 to 95.3 BPM). SpO2 remained 
high throughout the analysed time frame (Figure 5D; pre-administration mean: 98.5% and 
range: 94.3 to 99.6%, post-administration mean: 98.8% and range: 96.4 to 99.9%). 




Figure 5. Example of cerebral haemodynamics and global systemic changes for 60 s before and 180 s after midazolam 
administration at time 0 s for one drugging trial. Cerebral haemodynamics include [ΔHHb] (μ mol L−1), [ΔO2Hb] (μ mol 
L−1), relative cerebral blood volume changes [ΔtHb] (μ mol L−1), and relative haemoglobin oxygenation changes [ΔHbdiff] 
(μ mol L−1) in the (A) left and (B) right hemispheres of the brain. Systemic changes include (C) heart rate (BPM) and (D) 
SpO2 (%). All concentrations are expressed as relative changes from a baseline (0 μ mol L−1) at time of drug administration. 
This midazolam drugging trial was taken from Gruber on 06 December 2018 and was preceded by an initial intramuscular 
dose of midazolam, one intravenous dose of midazolam, and three intravenous ketamine doses. For combined raw data 
for all midazolam drugging trials see Supplementary Figures S5 and S6. [ΔHHb], change in concentration of deoxygenated 
haemoglobin; [ΔO2Hb], change in concentration of oxygenated haemoglobin; [ΔtHb], change in concentration of total hae-
moglobin; [ΔHbdiff], difference in concentration of oxygenated and deoxygenated haemoglobin; SpO2, arterial oxygen sat-
uration. 
3.2.2. Model Results 
The model predictions in response to midazolam showed that [ΔHHb] remained rel-
atively stable at around 0.0 μ mol L−1 prior to midazolam administration (Figure 6). After 
administration there was a marked increase in [ΔHHb] until 140 s after which there was 
a plateau at around 2.6 μ mol L−1 until 180 s. There was a marginal decrease in [ΔO2Hb] 
from −60 to 80 s (Figure 6). After 80 s, [ΔO2Hb] increased until 180 s. As for the ketamine 
model predictions, the response in [ΔO2Hb] to midazolam occurred at a lower magnitude 
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of change in comparison to [ΔHHb]. Further, the left (Figure 6A) and right (Figure 6B) 
hemispheres for the midazolam model predictions showed the same trends for the hae-
modynamic response variables with marginal differences in exact values of measure-
ments. 
The predicted mean heart rate showed a decrease from −60 to around 40 s, after which 
it increased for the remaining time frame of analysis (Figure 6). The changes in modelled 
heart rate were relatively small, ranging from 72.2 to 78.7 BPM. The 95% confidence inter-
vals were larger for the midazolam model predictions (Figure 6) than for the ketamine 
model predictions (Figure 3) across the [ΔHHb], [ΔO2Hb], and heart rate models. As for 
the response to ketamine, the model predictions for the response in SpO2 to midazolam 
administration remained relatively stable from −60 to 180 s with a range of 97.5 to 97.9% 
(Supplementary Figure S7).  
 
Figure 6. GAMM model prediction outcomes for [ΔHHb] (μ mol L−1), [ΔO2Hb] (μ mol L−1), and heart 
rate (BPM) in the (A) left hemisphere and (B) right hemisphere for 60 s before and 180 s after mid-
azolam administration at time 0 s for 11 trials across four grey seals. For illustrative purposes a 
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baseline shift was completed so that all concentrations are expressed as relative changes from a 
baseline (0 μ mol L−1) between the left and right hemispheres at time of drug administration. 
Changes in heart rate are systemic, meaning the presented model prediction outcomes for heart rate 
are the same for the left and right hemispheres. The shaded regions represent the 95% confidence 
intervals. GAMM, generalised additive mixed model; [ΔHHb], change in concentration of deoxy-
genated haemoglobin; [ΔO2Hb], change in concentration of oxygenated haemoglobin. 
The [ΔHHb] response to midazolam was modelled assuming Gaussian log link dis-
tribution of errors. The model with the lowest AIC retained all dependent variables except 
for the time since initial drugging (Equation (1) in the Supplementary Materials, Supple-
mentary Table S9). The [ΔO2Hb] response to midazolam was modelled assuming a Gauss-
ian distribution of errors. All covariates except for the time since initial drugging were 
retained in the model with the lowest AIC (Equation (2) in the Supplementary Materials, 
Supplementary Table S9). The heart rate response to midazolam was modelled assuming 
a Gaussian log link distribution of errors. The model with the lowest AIC retained all of 
the covariates included in model selection for heart rate (Equation (3) in the Supplemen-
tary Materials, Supplementary Table S9). The binomial family was used to model the re-
sponse of SpO2 and the model with the lowest AIC retained all variables included in 
model selection except midazolam bolus volume (Equation (4) in the Supplementary Ma-
terials, Supplementary Table S9). For model outputs of each response model see Supple-
mentary Tables S10–S13 in the supplementary materials. 
3.2.3. Breathing Rates  
The mean number of breaths over the 4 min analysis window of midazolam drugging 
trials was 8.5. Breathing was generally sporadic throughout the midazolam drugging tri-
als (Figure 7). There was a general decrease in the mean number of breaths during the 
analysis window, with an increase in the last 30 s interval. The mean number of breaths 
was generally lower for midazolam than for ketamine drugging trials, although midazo-
lam drugging trials also showed bouts of hyperventilation. For midazolam drugging tri-
als, the bouts of hyperventilation occurred within the 60 s before and 60 s after midazolam 
administration and 150 s after midazolam administration. 
 
Remote Sens. 2021, 13, 3553 19 of 27 
 
 
Figure 7. The mean number of breaths in 30 s intervals for 60 s before and 180 s after midazolam 
administration at time 0 s for 11 trials across four grey seals. Error bars represent the upper (75th 
percentile) and lower (25th percentile) quartile range of the data. 
4. Discussion 
Despite chemical immobilisation being a routine procedure in many animals, the 
physiological responses to anaesthetic and sedative agents in pinnipeds remains poorly 
understood [43]. To the best of our knowledge, this is the first study to use NIRS technol-
ogy to monitor brain haemodynamics and oxygenation of pinnipeds during anaesthesia. 
Data were collected using a customised neoprene headcap with integrated emitters and 
receivers of a continuous-wave NIRS device that measured real-time changes in received 
light intensity. While the predicted mean haemodynamic changes in response to midazo-
lam occurred at a smaller magnitude with greater variability, the haemodynamic response 
to both ketamine and midazolam showed an overall increase in [ΔHHb] and marginal 
decrease in [ΔO2Hb], which is indicative of apnoea. Further support for this response was 
seen in the decreasing mean number of breaths following the administration of both 
drugs. SpO2 remained high throughout all drugging trials, which suggests that cerebral 
oxygen delivery was maintained despite apnoea. Changes in heart rate appeared to be 
driven by the individual pharmacological actions of each drug since the response differed 
between ketamine and midazolam administration.  
Given that the seals in our study recovered safely from all experimental trials, the 
recorded haemodynamic measurements provide limits within which grey seals did not 
experience hypoxic injury. Further work is needed to define values that could provide an 
early warning for when intervention is needed if changes in [ΔHHb] and [ΔO2Hb] occur 
beyond the limits recorded in this study. That may be particularly useful given that ap-
noea is a common side-effect of pinniped anaesthesia and mortalities have occurred fol-
lowing anaesthesia-induced periods of apnoea within the aerobic dive limit of a species 
(i.e., the time beyond which a diving mammal depends on anaerobic metabolism for the 
remainder of a dive) [44,45]. Further, pre-existing conditions, such as verminous pneumo-
nia, have been linked to mortality following ketamine anaesthesia in pinnipeds [46]. If the 
clinical condition of the animal is unknown, NIRS could provide early warning signs of 
compromised cerebral oxygen supply and demand that would affect its ability to recover 
from the administration of certain anaesthetic agents.  
4.1. NIRS as a Monitoring Tool during Anaesthesia 
The continuous-wave NIRS system used here provided measurements of [ΔHHb] 
and [ΔO2Hb] in real-time and is therefore practical for monitoring of cerebral hemody-
namic and oxygenation changes during anaesthesia. However, the SpO2 and heart rate 
measurements used in this study were extracted retrospectively from [ΔHHb] and 
[ΔO2Hb]. Further development work would therefore be required to monitor these pa-
rameters in real time. In theory, the filters used for SpO2 and heart rate extraction could 
be run in tandem with the NIRS analysis software, Oxysoft, to provide real-time measure-
ments.  
The benefits of using NIRS to monitor anaesthetic effects include its high temporal 
resolution, its ability to measure oxygenation changes in response to interventions, its 
ability to monitor cerebral and systemic physiological changes, and the relative ease at 
which the technology can be transported and fitted to animals [47]. These features support 
the use of NIRS as a real-time physiological monitoring tool in the field and in captive 
facilities. Further support for the use of NIRS as an anaesthetic monitoring tool comes 
from its ability to measure differences in haemodynamic and oxygenation changes be-
tween types of anaesthetic agents [48] and various concentrations of the same agent [49].  
Despite its potential, there are some limitations associated with the use of NIRS tech-
nology. Confounding factors such as motion artefacts or improper contact between optical 
probes and the skin may interfere with the recorded signals. Several studies using NIRS 
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during human anaesthesia have found that changes in head position affect the recorded 
haemodynamic measurements [50–52]. The use of NIRS as a monitoring tool during pin-
niped anaesthesia would require the initial administration of a sedative or anaesthetic 
agent, as used in our drugging methodology, to ensure the animal remains still during 
optode attachment. Additionally, operators should ensure that optodes remain properly 
attached following instances of movement.  
Another consideration is that NIRS measures regional oxygenation changes in areas 
of optode attachment. While the data used for our study were taken from a 28 channel 
NIRS system, for processing efficiency the analysis was limited to data derived from a 
single channel in each hemisphere. Nonetheless, the analysed patterns of haemodynamic 
changes and the gross physiological signals were broadly similar between the two inde-
pendent channels and visual inspection of the other channels showed similar trends. Fur-
ther, the magnitude of change in response to regional activation is much lower than that 
of the systemic level changes analysed in this study. For this reason, the results from our 
study were likely not affected by the seals’ involvement in other experimentation during 
anaesthesia. The changes in response variables expected from those experiments were be-
low 1 μ mol L−1 [31], whereas the systemic changes related to drugging events occurred at 
magnitudes up to 19 μ mol L−1. The monitoring of systemic level changes would inform 
operators of a global cerebral response, such as apnoea, which may compromise cerebral 
integrity and therefore it is not necessary to analyse regional cortical activation for physi-
ological monitoring of pinnipeds under anaesthesia. The use of a single channel system 
within each hemisphere would improve the ease of attachment and interpretation of NIRS 
data for seals under anaesthesia, while still providing real-time cerebral monitoring of 
systemic changes. Alternatively, the use of three optode-detector separation distances, 
and therefore three channels in each hemisphere, could provide the additional measure 
of Tissue Saturation Index (TSI); an absolute measure of oxygenated haemoglobin. 
Given that we analysed systemic level changes, extracerebral signals from short 
channels were not subtracted from deeper haemodynamic signals of the two long chan-
nels, which were chosen for analysis. While the channels chosen for analysis provided 
identifiable patterns of haemodynamic changes in response to drugging, these measure-
ments were likely affected by some degree of extracerebral signal contamination and fu-
ture work using short channel regression could help to refine cortical data received from 
potential monitoring NIRS systems [53]. 
Although we found a global cerebral response to drugging, the ‘Side (left or right 
hemisphere)’ factor variable was retained in both haemodynamic models for ketamine 
and midazolam. The magnitude of difference between the modelled measurements of the 
two hemispheres was less than the system noise of the NIRS device, which occurs even 
when the device is not used on living beings. Given that both the physiological makeup 
of living beings and the optode attachment on seals in our study are not perfectly sym-
metrical, it is unlikely that the hemispheres would provide the same signal, even in global 
systemic changes. However, there may still have been slight system or mechanical differ-
ences between the optodes of each side that were causing a consistent change in the values 
measured from the left and right hemispheres. The experiments used for this study rep-
resent the first time that a multichannel NIRS system has been used on a non-domesti-
cated animal and if this system were to be developed in practice to monitor anaesthesia, 
the difference between the hemisphere measurements would need to be explored further.  
Given the novel application of a multichannel NIRS system to measure cerebral hae-
modynamics and oxygenation in an animal, some assumptions were made about the op-
tical properties of seal haemoglobin and cerebral tissue. The assumptions were based on 
those made by McKnight et al., 2019 [5] and were unlikely to affect the systemic level of 
changes analysed in our study. Further, if the optical properties did not adhere to our 
assumptions, only the magnitude of change would be affected, meaning patterns of rela-
tive changes in [ΔHHb] and [ΔO2Hb] would remain the same, thus not affecting any of 
the physiological parameters studied here.  
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If developed further, the use of NIRS may help researchers and veterinarians over-
come some of the risks from chemical immobilisation in pinnipeds by providing early 
indicators of when an intervention may be needed. This could help advance surgical pro-
cedures requiring safe protocols for sedation or anaesthesia. The risks of heavy anaesthe-
sia, in particular, are a prominent limitation in performing surgical procedures on marine 
mammals [54], meaning the use of a reliable anaesthetic monitoring tool would encourage 
the use of surgery as a suitable option for diagnostics and treatment in pinnipeds. Given 
that other marine mammal species face comparable anatomical challenges, the use of 
NIRS could be broadened to monitor cerebral integrity during anaesthesia for several ma-
rine mammal species that face risks of anaesthesia.  
4.2. Physiological Responses to Drugging 
The overall trends in haemodynamic measurements made here for ketamine and 
midazolam are representative of the cerebral response to apnoea. While drugging trials 
showed patterns of episodic breathing, the number of breaths generally decreased follow-
ing drug administration for both ketamine and midazolam. Breathing patterns for keta-
mine drugging trials, in particular, were characterised by initial bouts of hyperventilation 
followed by prolonged periods of apnoea up to 3.5 min. When comparing the respiratory 
band and [ΔO2Hb] data of individual drugging trials it was evident that the observed 
increase in [ΔHHb] and decrease in [ΔO2Hb] frequently occurred at the onset of apnoea 
following re-oxygenation (see Supplementary Figure S8). Hyperventilation was likely to 
have been the result of the anaesthetic effects of previous drug doses wearing off as mov-
ing around and contacting the animals was kept to a minimum.  
Drugging trials were also characterised by a high SpO2, around 97%, and increasing 
[ΔtHb], which suggests that arterial blood oxygen delivery to the brain was maintained 
despite drug-induced periods of apnoea. The concomitant increase in [ΔHHb] could be 
explained by increased metabolic rate causing the rate of oxygen consumption to exceed 
the rate of oxygen delivery to the brain. However, it remains unlikely that metabolic rate 
influenced the increase in [ΔHHb], given the magnitude of response observed in this 
study. Further, neuronal activation typically causes arterial vasodilation and a surge in 
oxygen supply, which exceeds the demand, meaning [ΔO2Hb] would also be increasing 
under this haemodynamic epiphenomenon [47].  
We suggest that increasing [ΔHHb] was more likely a result of venous congestion 
during apnoea. Similar haemodynamic changes representative of venous congestion have 
been observed in harbour seals in anticipation of diving [5]. When increased arterial de-
livery is paired with increased venous drainage, cerebral oxygenation increases [5]. How-
ever, under venous congestion, arterial delivery of oxygenated blood is not matched with 
increased venous drainage, causing the relative contribution of [ΔHHb] and [ΔtHb] to 
increase while cerebral oxygenation decreases [55,56]. Given that [ΔO2Hb] remained rela-
tively stable, the increases in [ΔtHb] observed in our raw data (Figures 2 and 5) were likely 
a function of increasing [ΔHHb], for ketamine and midazolam druggings. In addition, the 
periods of hyperventilation primarily observed at the beginning of drugging trials and 
the high SpO2 suggests that seals were well oxygenated at the onset of apnoea, despite 
increasing [ΔHHb].  
Venous congestion may be a result of a mechanical blockage in drainage vessels or 
increased central venous pressure [57–60]. The periods of hyperventilation observed in 
our results were typically characterised by an initial exhalation followed by inhalation, 
suggesting that the seals’ lungs were filled throughout periods of apnoea (Supplementary 
Figure S8) [31]. Therefore, we propose that venous congestion was a result of increased 
central venous pressure induced by maintaining positive pressure in the lungs. The same 
mechanisms occur in the Valsalva Manoeuvre, which is associated with the breathing me-
chanics of phocid seals. In the Valsalva Manoeuvre, exhalation is attempted against a 
closed airway and the preceding inspiratory gasp causes increased intrathoracic pressure. 
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As a result, central venous pressure increases, causing decreased cerebral venous outflow 
and a concomitant increase in intracranial pressure [61,62].  
In our drugging trials, the seals’ maintenance of high SpO2 suggests that venous con-
gestion did not affect cerebral oxygen delivery during apnoea. However, if anaesthetised 
seals undergo reduced cerebral oxygenation over longer periods of apnoea than seen in 
our study, it is possible that they could risk facing cerebral metabolic dysfunction or ele-
vated intracranial pressure. Future research should make simultaneous measurements of 
cerebral metabolism to investigate whether venous congestion could limit the amount of 
[ΔO2Hb] available for cerebral metabolism with broadband NIRS measures of change in 
concentration of oxidised cytochrome-c-oxidase ([ΔCCO]) [63]. The additional measure of 
[ΔCCO] could guide researchers in determining when apnoea should be considered pro-
longed if changes in [ΔHHb] and [ΔO2Hb] occur beyond the limits recorded in this study. 
The response in heart rate to ketamine administration in this study supports keta-
mine-induced changes in arterial blood pressure recorded in previous studies conducted 
on dogs [64] and sheep [65]. The initial decrease in heart rate could be attributed to a direct 
depressant effect of ketamine on the myocardium, which was observed in isolated rabbit 
[64] and guinea pig hearts [66]. The subsequent increase in heart rate may then have been 
the result of central nervous system activation, which overrides the peripherally mediated 
depressant effects at lower doses [65]. Support for the centrally mediated cardiovascular 
stimulatory effects of ketamine comes from that fact that they can be attenuated by central 
nervous system depressants such as benzodiazepines [67]. The model predictions for mid-
azolam showed a decrease in heart rate pre-administration, which persisted until approx-
imately 40 s at which point heart rate increased. The point at which heart rate increased 
likely represents midazolam’s onset of action. Midazolam has a rapid onset of action of 30 
to 60 s when administered intravenously [15]. The increase in heart rate is typically a result 
of the decrease in systemic vascular resistance caused by midazolam [15]. Simultaneous 
measures of blood pressure changes throughout chemical immobilisation could provide 
further support for these conclusions on the pharmacological actions of each drug. 
For both ketamine and midazolam, the raw heart rate data were variable, which is 
typical of seals. However, the predicted mean heart rate for both drugs remained between 
69 and 79 BPM throughout the analysis windows. Since we did not have measurements 
of resting heart rate before chemical immobilisation, we can compare our measurements 
of heart rate to that of unanaesthetised elephant seals, which experience similar changes 
in heart rate to grey seals during apnoea on land and whilst diving [68,69]. In juvenile 
northern elephant seals the mean apnoeic and eupnoeic heart rates are 45 and 65 BPM, 
respectively, during periods of quiet wakefulness or sleep on land [68]. Assuming grey 
seals in our study experienced a similar range in heart rate before drugging, chemical im-
mobilisation caused a moderate increase in heart rate, which suggests that ketamine ex-
erted some stimulatory effects on the cardiovascular system during anaesthesia. In an-
other study, in which ketamine was used as the sole immobilising agent, northern ele-
phant seals experienced a mean increase of 13 BPM in heart rate following immobilisation 
[14]. Given the range in heart rate experienced following ketamine and midazolam ad-
ministrations in our study, it is unlikely that our levels of midazolam dosage significantly 
dampened the cardiostimulatory effects of ketamine.  
4.3. Additional Modelling Interpretations 
In this study, GAMM models were used to create predictions for the response of the 
dependent variables to ketamine or midazolam. The mass of individual seals on the date 
of experimentation was not included in statistical modelling because intravenous drug 
doses were administered based on individual response as opposed to mass. Additionally, 
differences in mass would only affect the magnitude of systemic changes and duration of 
recovery [70–72]. The model for the response of [ΔO2Hb] to ketamine retained all covari-
ates whereas the model for [ΔHHb] did not retain the respiratory band data. This is likely 
due to the influence of breath-holding on blood oxygen levels. For midazolam [ΔHHb] 
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and [ΔO2Hb] model selection, the ‘time since initial drugging’ covariate was not retained. 
Midazolam is a short-acting benzodiazepine and therefore does not accumulate after re-
peated doses [73]. The time since initial drugging may therefore not have been a signifi-
cant factor in predicting the response to midazolam because the effects of the initial intra-
muscular dose subsided before the first intravenous dose of midazolam was adminis-
tered. In contrast, the ‘midazolam bolus volume’ covariate was retained in all midazolam 
models. This could have been the result of accumulated ketamine doses altering the mag-
nitude of response to midazolam. 
The model predictions for responses in [ΔHHb], [ΔO2Hb], and heart rate to midazo-
lam had greater variability than for ketamine, as seen in the 95% confidence intervals of 
Figure 6. This could be attributed to the lower sample size of midazolam and the varying 
levels of potency in ketamine between midazolam drugging trials. Since ketamine was 
administered more frequently than midazolam, we expected the trends in response to 
ketamine to be reflected in the response to midazolam. In addition, since midazolam was 
used to limit the physiological impacts of ketamine, we expected to see relatively smaller 
magnitudes of change in response to midazolam. Indeed, the [ΔO2Hb] and [ΔHHb] model 
predictions for midazolam could be suggestive of a dampened response to ketamine. De-
spite ketamine and midazolam’s opposing mechanisms of actions, which typically result 
in opposite physiological responses as observed in humans [13,15], our study showed a 
similar trend in [ΔO2Hb] and [ΔHHb] in response to both drugs, as a result of apnoea, 
which causes a global cerebral response. On the contrary, the trend in heart rate was dif-
ferent following the administration of ketamine and midazolam, which suggests that 
heart rate was driven by the individual mechanisms of action of each drug.  
5. Conclusions 
An understanding of the pharmacology of anaesthetic agents and real-time physio-
logical monitoring is essential to ensure safe chemical immobilisation procedures. The 
purpose of the current study was to investigate the effect of ketamine and midazolam on 
heart rate, arterial oxygen saturation (SpO2), and cerebral haemoglobin oxygenation of 
grey seals using near-infrared spectroscopy (NIRS) and to establish whether NIRS could 
provide real time, non-invasive physiological monitoring during chemical immobilisa-
tion. The haemodynamic findings from this study showed that the onset of apnoea dom-
inated the cerebral response to drugging. Given that SpO2 remained high, we hypothe-
sised that cerebral deoxygenation in response to ketamine and midazolam druggings was 
a result of venous congestion. Given the safe induction and recovery from anaesthesia, 
the haemodynamic changes observed in the current study represent limits within which 
seals recovered safely and experienced no adverse side effects. Beyond these limits, 
measures of oxygen delivery would need to be supported with measures of utilisation to 
assess whether there is a threat of metabolic dysfunction. In conclusion, the findings from 
this study support the use of NIRS technology as basis for a tool to study the physiological 
effects of anaesthetic agents and to monitor the cerebral response during chemical immo-
bilisation of pinnipeds These insights may be of assistance to veterinarians and research-
ers that require safe chemical immobilisation procedures.  
Supplementary Materials: The following are available online at www.mdpi.com/arti-
cle/10.3390/rs13183553/s1, Table S1: The capture dates of the individual seals included in the exper-
imental trials, Table S2: Mass (kg), girth (cm), and length (cm) of individual seals on the dates of the 
experimental procedures, Table S3: The number of drugging trials for each individual seal that were 
used in analysis for the effects of ketamine and midazolam, Example model selection code, Figure 
S1: Example of cerebral haemodynamics and global systemic changes for a series of ketamine and 
midazolam druggings administered in succession, Figure S2: Cerebral haemodynamics of (A) 
[ΔHHb] (μ mol L−1) and (B) [ΔO2Hb] (μ mol L−1), (C) heart rate (BPM), (D) relative cerebral blood 
volume changes [ΔtHb] (μ mol L−1), and (E) relative haemoglobin oxygenation changes [ΔHbdiff] (μ 
mol L−1) for 60 s before and 180 s after ketamine administration at time 0 s for n=27 trials across five 
grey seals, Figure S3: The SpO2 (%) for 60 s before and 180 s after ketamine administration at time 0 
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s for n = 23 trials across five grey seals, Figure S4: GAMM model prediction outcomes for SpO2 (%) 
60 s before and 180 s after ketamine administration at time 0 s for n=23 trials across five grey seals, 
Table S4: GAMM equations for [ΔHHb] (μ mol L−1), [ΔO2Hb] (μ mol L−1), heart rate (BPM), and SpO2 
(proportion of [ΔO2Hb] to [tHb]) for 60 s before and 180 s after ketamine administration at time 0 s 
for n number of trials across five grey seals, Table S5: The estimates and standard error for coeffi-
cients of a GAMM of the response in [ΔHHb] (μ mol L−1) to ketamine injection (n = 27) across five 
grey seals (Equation (1), Table S4), Table S6: The estimates and standard error for coefficients of a 
GAMM of the response in [ΔO2Hb] (μ mol L−1) to ketamine injection (n = 27) across five grey seals 
(Equation (2), Table S4), Table S7: The estimates and standard error for coefficients of a GAMM of 
the response in heart rate (BPM) to ketamine injection (n = 27) across five grey seals (Equation (3), 
Table S4), Table S8: The estimates and standard error for coefficients of a GAMM of the response in 
SpO2 (proportion of [ΔO2Hb] to [tHb]) to ketamine injection (n = 23) across five grey seals (Equation 
(4), Table S4), Figure S5: Cerebral haemodynamics of (A) [ΔHHb] (μ mol L−1) and (B) [ΔO2Hb] (μ 
mol L−1), (C) heart rate (BPM), (D) relative cerebral blood volume changes [ΔtHb] (μ mol L−1), and 
(E) relative haemoglobin oxygenation changes [ΔHbdiff] (μ mol L−1) for 60 s before and 180 s after 
midazolam administration at time 0 s for n=11 trials across four grey seals, Figure S6: The SpO2 (%) 
for 60 s before and 180 s after midazolam administration at time 0 s for n = 9 trials across four seals, 
Figure S7: GAMM model prediction outcomes for SpO2 (%) 60 s before and 180 s after midazolam 
administration at time 0 s for n=9 trials across four grey seals, Table S9: GAMM equations for [HHb] 
(μ mol L−1), [ΔO2Hb] (μ mol L−1), heart rate (BPM), and SpO2 (proportion of [ΔO2Hb] to [tHb]) for 60 
s before and 180 s after midazolam administration at time 0 s for n number of trials across four grey 
seals, Table S10: The estimates and standard error for coefficients of a GAMM of the response in 
[ΔHHb] (μ mol L−1) to midazolam injection (n = 11) across four grey seals (Equation (1), Table S9), 
Table S11: The estimates and standard error for coefficients of a GAMM of the response in [ΔO2Hb] 
(μ mol L−1) to midazolam injection (n = 11) across four grey seals (Equation (2), Table S9), Table S12: 
The estimates and standard error for coefficients of a GAMM of the response in heart rate (BPM) to 
midazolam injection (n = 11) across four grey seals (Equation (3), Table S9), Table S13: The estimates 
and standard error for coefficients of a GAMM of the response in SpO2 (proportion of [ΔO2Hb] to 
[tHb]) to midazolam injection (n = 9) across four grey seals (Equation (4), Table S9), Figure S8: (A) 
The corrected respiratory band measurements (mV) for an experimental trial with multiple intrave-
nous administrations of ketamine and midazolam and (B) the corrected respiratory band measure-
ments (mV) and (C) haemodynamic measurements (μ mol L−1) of a single ketamine drugging trial. 
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